But not limited to.

Pharmaceutical Product Development nature involves substantial risks and uncertainties. For more information about factors that cause the results of Jazz Pharmaceuticals to differ materially from expectations, reference to the risks set forth under Risk Factors and elsewhere in the form S-1 Registration Statement of 31 explained presented, filed 2007 Jazz Pharmaceuticals with the Securities and Exchange Commission. The actual results may differ. From the expectations of Jazz Pharmaceuticals due to these risks and uncertainties Jazz Pharmaceuticals assumes no liability or obligation to update any forward-looking statements in this news release to update , as a result of new information, future events or changes in expectations of Jazz Pharmaceuticals.

Pharmaceuticals submission of complete responses to FDA Approvable Letters for Luvox CR and Luvox Jazz Pharmaceuticals today announced that the U.S. Food and Drug Administration has for review of the submission of the complete response by Solvay Pharmaceuticals, the FDA accepts recommendation for approval of Luvox CR Extended – Release Capsules. The PDUFA action date 22 December 2007.Well-defined definition from NERD about clinical trials. .. PPI treating primary endpoint the selected studies is defined as complete or partial heartburn Relief Two reviewers independently extracted dates and assessed trial quality of selected articles Random effects models of and meta-regression were used for combining and results to analyze. The pooled estimate of complete exemption heartburn after 4 weeks of PPI therapy to patients with EARTH was 0.72 , 57) in treated patients empirical, in Boston, Massachusetts) in patients than non-erosive. Through negative endoscopy and 0.77) into in than non-erosive patients of both negative and the positive endoscopic pH testing Defining conclusions of and conclusions about NERD patients fine, the estimated complete symptom return rate according PPI therapy similar to response of patients by EARTH.

According to to the reporters, the researchers concluded: ‘The previous low response rate reporting at studies of patients being listed as NERD probably the results of the inclusion for patients with upper GI symptoms, not oesophageal reflux disease ‘.